Jasper Therapeutics, Inc. (JSPR)

US — Healthcare Sector
Peers: EFTR  ENSC  HOWL  PALI  RNAZ  SPRB  UNCY 

Automate Your Wheel Strategy on JSPR

With Tiblio's Option Bot, you can configure your own wheel strategy including JSPR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol JSPR
  • Rev/Share 0.0805
  • Book/Share 2.8964
  • PB 1.1635
  • Debt/Equity 0.0613
  • CurrentRatio 4.3112
  • ROIC -1.793

 

  • MktCap 50624477.0
  • FreeCF/Share -4.8156
  • PFCF -0.7208
  • PE 3.5803
  • Debt/Assets 0.045
  • DivYield 0
  • ROE 0.1907

 

  • Rating A+
  • Score 4
  • Recommendation Buy
  • P/E Score 3
  • DCF Score 4
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade JSPR BMO Capital Markets Outperform Market Perform -- $4 July 8, 2025
Downgrade JSPR RBC Capital Mkts Outperform Sector Perform -- $5 July 8, 2025
Downgrade JSPR William Blair Outperform Market Perform -- -- July 7, 2025
Downgrade JSPR Cantor Fitzgerald Overweight Neutral -- -- July 7, 2025
Initiation JSPR UBS -- Buy -- $38 Feb. 13, 2025
Initiation JSPR BMO Capital Markets -- Outperform -- $63 Dec. 6, 2024
Initiation JSPR JMP Securities -- Mkt Outperform -- $70 Sept. 9, 2024

News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
JSPR
Published: July 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
JSPR
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

REDWOOD CITY, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that four abstracts have been accepted for presentation at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasgow, United Kingdom. Jasper will present initial clinical data from patients enrolled in the 180mg cohort of the SPOTLIGHT Phase 1b/2a study evaluating briquilimab in subcutaneous briquilimab in …

Read More
image for news Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
JSPR
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2024 and provided a corporate update.

Read More
image for news Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

About Jasper Therapeutics, Inc. (JSPR)

  • IPO Date 2020-01-10
  • Website https://jaspertherapeutics.com
  • Industry Biotechnology
  • CEO Ronald A. Martell
  • Employees 64

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.